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SAVINGS OF THE USE OF RHBMP-2 IN OPEN TIBIA
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2Abacus International, Bicester, UK, 3University Hospital Giessen,
Location Giessen, Giessen, Germany
OBJECTIVES: Recombinant human bone morphogenetic
protein (rhBMP2) is a growth factor for new bone formation.
The objective was to calculate cost savings for the use of rhBMP-
2 in grade III open tibia fractures for Germany, France and UK
from a public health care system and a societal perspective,
respectively. METHODS: A health economic model was devel-
oped based on clinical data from a previously published ran-
domized controlled trial (BESTT study) comparing rhBMP-2 +
standard of care (soft tissue management and intramedullary
nailing) with standard of care alone. Clinical data were trans-
ferred using reimbursement 2005 tariffs (German-DRG, UK-
NHS, French-Social Security tariffs) and published data for
sickness payments and productivity loss for a one year time
horizon. RESULTS: In Germany and France sickness payments
are provided by public health care insurances and therefore, the
payer perspective is identical to the societal perspective. In
Germany, the use of rhBMP-2 for grade III open tibia fractures
savings of direct costs of 1359 € per patient and of 2714 € for
sickness payment resulting in total savings of 4073 € per patient
that offset the price of rhBMP2 (2950 €). For France, there are
total savings of 3476 € with savings in direct costs of 1197 € and
in indirect costs of 2279 € which outbalance the price of rhBMP-
2. For UK, rhBMP-2 achieves savings of ≤1126 from a payer per-
spective which is below price of rhBMP-2 (≤1790). However,
from a UK societal perspective total savings of ≤5139 make
rhBMP-2 a cost saving strategy. For all three different countries
the major driver for cost savings is the faster fracture healing
with reduced expenses for sickness leave payments and produc-
tivity gain, respectively. CONCLUSION: rhBMP-2 is a cost
saving strategy in grade III open tibia fractures from a payer per-
spective for Germany and France and from a societal perspec-
tive for UK.
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OBJECTIVES: To examine the relationship of admissions to dis-
charges in the availability of inpatient beds at a medium sized
southern hospital. METHODS: Data collected from several EDs
were modeled using time series analysis to investigate the rela-
tionship of time of admission to length of stay; in addition, dis-
charge data were collected to examine the time between
admission and discharge to see if the time lag is related to bed
availability. RESULTS: In the emergency department (ED) where
arrivals can occur randomly, the peak time is between 9AM and
5PM in one hospital, increasing the length of stay for non-urgent
patients while patients admitted to inpatient beds have consid-
erable variability in their stay in the ED. At a second hospital,
the peak time occurred at 3PM during the standard time of shift
change. In addition, there is a time lag in beds, with admissions
trailing discharges. CONCLUSION: Time series forecasting can
ﬁnd problems in the availability of beds; once identiﬁed, the
problems can be solved. These time series techniques can be used
to drill down into every 24-hour period to examine where
increased waiting times result for bed unavailability.
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OBJECTIVES: To assess the effectiveness of pharmacist consul-
tation service in increasing patient medication adherence by
applying the instrumental variable (IV) method to adjust for
endogeneity. METHODS: This study used the Kaiser Permanente
(KP) pharmacist consultation intervention survey data from
1993 to 1995. The effect of pharmacist consultation on med-
ication adherence was measured via patients’ satisfaction with
the service using patient ratings. Treating this variable as exoge-
nous, a single-equation probit model was used. To address the
endogeneity, bivariate probit models were employed using dif-
ferent sets of instrumental variables (IVs). The IVs used were
measures of patients’ optimism, as well as the business of a KP
pharmacy by measuring the amount of prescriptions ﬁlled at
non-KP pharmacies. Smith-Blundell test was used to test the
endogeneity. Over-identiﬁcation tests were used to test the valid-
ity of the IVs. The weak instrument test was used to evaluate the
IVs’ explanatory powers. RESULTS: All tests indicated that the
IVs used were valid and the results were signiﬁcant. The single-
equation probit model renders that patients’ satisfaction with
pharmacist consultation has signiﬁcant effect on medication
adherence (p < 0.0001). The bivariate probit models using dif-
ferent sets of IVs exhibit that the single-equation probit model
underestimated the magnitude of the effect because of the endo-
geneity bias; the marginal effect of patients’ satisfaction with
pharmacist consultation on medication adherence increased
from 0.06 to about 0.27 after using bivariate probit models 
(p < 0.0001). In other words, once the endogeneity bias was cor-
rected, pharmacist consultation demonstrated a greater impact
on patient medication adherence. CONCLUSION: Pharmacist
consultation plays a signiﬁcant role in health care. Its effect can
be evaluated on patient medication adherence via patient satis-
faction with the service. This study reveals that the effect of this
service was signiﬁcant before addressing the endogeneity and, the
magnitude of the effect increased after the endogeneity was
removed.
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OBJECTIVES: Examine the impact of adjusting for price differ-
ences (conversion to international dollars), as advocated by the
World Health Organization (WHO), when conducting cost-
effectiveness analyses in developing nations. METHODS: We
created a hypothetical cost-effectiveness analysis, set in India,
with 2 strategies: standard care (STD-CARE) and intervention.
Two costing methods were used: unadjusted exchange rate
(XCHG), and international dollars (I$) where non-traded goods
(e.g. services or locally traded goods) and per-capita gross
domestic product (GDP) were adjusted for international price
differences using purchasing power parity (PPP) estimates from
WHO. Three different interventions were considered: 1) Costs
are all internationally traded goods (TRADED); 2) Costs are all
